Atara Biotherapeutics (Nasdaq: ATRA) has announced it will stop developing its kidney drug PINTA 745 after it failed to meet its primary endpoint.
Shares in the company plunged 36.75% to $21.00 following the announcement yesterday, and dipped a further to $20.27 in pre-market trading this morning.
The drug aimed to treat patients with end stage renal disease by blocking the protein, mysostatin and improving kidney function but it did not achieve the main goal of the study which was defined as the percent change from baseline in Lean Body Mass (LBM) as measured by Dual Energy X-Ray Absorptiometry (DXA) at week 12 following weekly treatment with PINTA 745.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze